|
|
Post by mnholdem on Jun 13, 2018 16:01:08 GMT -5
MannKind (MNKD) Phase 1 Data Hints at ‘Transformational’ PAH Drug, Cheers H.C. Wainwright
H.C. Wainwright's Oren Livnat sees compelling potential for MNKD's dry powder inhalation PAH drug to grab substantial share or "grow the market." Julie Lamb, Senior Editor-June 13, 2018, 3:41 PM ET Excerpt:
H.C. Wainwright analyst Oren Livnat is out with an upbeat research note on MannKind (NASDAQ:MNKD) and its prospective pulmonary arterial hypertension (PAH) innovation, Technosphere treprostinil. Last Thursday, the biotech player released positive Phase 1 data of its dry powder inhalation designed for PAH and with impressive timing- “months ahead of schedule.” Livnat cheers this as a key indication that MNKD”s inhalation asset delivery platforms pose prospectively vastly “more value” when weighed up against “just” Afrezza inhalable insulin.
Therefore, the analyst reiterates a Buy rating on MNKD stock with a $2 price target, which implies a 5% upside from current levels.
Though Livnat is not factoring in the PAH asset so far in his expectations, he nonetheless sees a powerhouse drug that could become “transformational.” Consider that United Therapeutics’ PAH treprostinil franchise circles beyond $1.1 billion in sales this year translating to more than $500 million for parenteral Remodulin, $375 million for inhalable Tyvaso, as well as $240 million for oral Orenitram. Source: www.smarteranalyst.com/analyst-insights/biotech-stocks/mannkind-mnkd-phase-1-data-hints-transformational-pah-drug-cheers-h-c-wainwright/
|
|
|
|
Post by mytakeonit on Jun 13, 2018 16:31:26 GMT -5
Really? $2 price target?!!! Okay peppy ... show him what you can do tomorrow and Friday.
|
|
|
|
Post by sportsrancho on Jun 13, 2018 16:37:05 GMT -5
Really? $2 price target?!!! Okay peppy ... show him what you can do tomorrow and Friday. I guess we can call this the “dump and pump”😂 |
|
|
|
Post by mytakeonit on Jun 13, 2018 16:42:33 GMT -5
Let's see ... Comcast bid $65B for Fox ... and we get a $2 price target. HEY ... MNKD should bid $66B for Fox ... that'll get us in the news!
Or, I'll put a sell order out for 100 shares of MNKD at $100 pps. Then, kite can buy it and make Wainwright look stupid. Oops! Too late ... he already looks stupid.
|
|
|
|
Post by compound26 on Jun 13, 2018 17:05:58 GMT -5
That price target of $2 is most likely a typo. I am 99% sure of that.  There are a few reasons. 1. First, the articles says he is reiterating a buy rating. You do not have a "buy" rating when the shares are trading at $1.93+ and you have a price target at $2. There is basically no upside, then what is the rationale for you to "buy"?
2. Second, since he is "reiterating" a buy rating, let's see what was his last rating. His last rating was issued on June 7 and the price target was $5.
www.analystratings.com/articles/analysts-offer-insights-on-healthcare-companies-miragen-therapeutics-inc-nasdaq-mgen-athersys-nasdaq-athx-and-mannkind-nasdaq-mnkd/
MannKind (NASDAQ: MNKD)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on MannKind (NASDAQ: MNKD), with a price target of $5. The company’s shares opened today at $2.03, close to its 52-week low of $1.09.
Livnat wrote:
“We believe the existing treprostinil formulations suffer from clear deficiencies with very complicated and onerous drug delivery and/or dosing-limitations which likely limit efficacy. Due in large part to these limitations, in our view, prostacyclins are only used by about 20% of the 30,000 diagnosed U.S. PAH patients despite 80% being eligible. MannKind will pursue an expedited 505(b)2 bioequivalence pathway now, and could start a pivotal Tyvaso switching study in PAH patients in 2H18. We will wait to see some data first, but theoretically, TreT could be filed by end-2019 and get some credit from the market soon. If successful, we are confident that Technosphere treprostinil, or “TreT,” could represent a material innovation in the PAH prostacyclin space, even with only switching and bioequivalence data.”
So what can I say. Sloppy editors!!! But is that intentional? Who knows. Anything can happen with respect to Mannkind. |
|
|
|
Post by tingtongtung on Jun 13, 2018 17:06:25 GMT -5
Let's see ... Comcast bid $65B for Fox ... and we get a $2 price target. HEY ... MNKD should bid $66B for Fox ... that'll get us in the news! Or, I'll put a sell order out for 100 shares of MNKD at $100 pps. Then, kite can buy it and make Wainwright look stupid. Oops! Too late ... he already looks stupid. I thought these guys had a $5 on MNKD? They all look the same :-( Anyway, there's a weird stability for a while (~1.9x), and then dropped to 1.80s.. Depressing, but a good day today. I hope the scripts continue their steady increase. But, we need much, much higher numbers soon. |
|
|
|
Post by sportsrancho on Jun 13, 2018 17:44:58 GMT -5
Therefore, the analyst reiterates a Buy rating on MNKD stock with a $2 price target, which implies a 5% upside from current levels. (To watch Livnat’s track record, click here)
Then that whole thing is a typo? Crossing my fingers!
|
|
|
|
Post by boca1girl on Jun 13, 2018 18:25:34 GMT -5
MannKind (MNKD) Phase 1 Data Hints at ‘Transformational’ PAH Drug, Cheers H.C. Wainwright
H.C. Wainwright's Oren Livnat sees compelling potential for MNKD's dry powder inhalation PAH drug to grab substantial share or "grow the market." Julie Lamb, Senior Editor-June 13, 2018, 3:41 PM ET Excerpt:
H.C. Wainwright analyst Oren Livnat is out with an upbeat research note on MannKind (NASDAQ:MNKD) and its prospective pulmonary arterial hypertension (PAH) innovation, Technosphere treprostinil. Last Thursday, the biotech player released positive Phase 1 data of its dry powder inhalation designed for PAH and with impressive timing- “months ahead of schedule.” Livnat cheers this as a key indication that MNKD”s inhalation asset delivery platforms pose prospectively vastly “more value” when weighed up against “just” Afrezza inhalable insulin.
Therefore, the analyst reiterates a Buy rating on MNKD stock with a $2 price target, which implies a 5% upside from current levels.
Though Livnat is not factoring in the PAH asset so far in his expectations, he nonetheless sees a powerhouse drug that could become “transformational.” Consider that United Therapeutics’ PAH treprostinil franchise circles beyond $1.1 billion in sales this year translating to more than $500 million for parenteral Remodulin, $375 million for inhalable Tyvaso, as well as $240 million for oral Orenitram. Source: www.smarteranalyst.com/analyst-insights/biotech-stocks/mannkind-mnkd-phase-1-data-hints-transformational-pah-drug-cheers-h-c-wainwright/ Maybe he meant to say the contribution from TreT is worth $2 a share alone, therefore the new price target is $7. I agree that his price target was $5 and he reiterated $5 last week. But I liked what he had to say about TreT. |
|
|
|
Post by dh4mizzou on Jun 14, 2018 6:54:18 GMT -5
Seems like the word "transformational" is being applied to every drug that MNKD has come out with.
|
|
|
|
Post by liane on Jun 14, 2018 7:22:19 GMT -5
Well, I would call it transformational if it delivers a drug effectively, conveniently, discretely, and painlessly.
|
|
|
|
Post by mnholdem on Jun 14, 2018 7:54:17 GMT -5
The $2 "reiteration" on the June 13 article does seem to be a misprint because Oren's last target call on MNKD was published only a month ago (May 10):
"...while H.C. Wainwright analyst Oren Livnat sticks tight with the bulls, he dials down his target expectations. The company’s innovative asset Afrezza, a rapid-acting, inhaled mealtime insulin for Type 1 and Type 2 diabetes is experiencing a more sluggish-to-take-off ramp than Livnat anticipated.
"On back of the quarterly earnings show, the analyst reiterates a Buy rating on MNKD stock while dialing the price target from $7 to $5, which implies a 184% upside from current levels. "
Source: www.smarteranalyst.com/analyst-insights/h-c-wainwright-sticks-bulls-mannkind-mnkd-lowers-price-target-sluggish-afrezza-adoption/
|
|
|
|
Post by wyattdog on Jun 14, 2018 9:51:33 GMT -5
osted by Jesse Mackey on Jun 7th, 2018 // No Comments
MannKind logoMannKind (NASDAQ:MNKD) received a $5.00 target price from equities research analysts at HC Wainwright in a research note issued on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 151.26% from the company’s previous close.
A number of other equities analysts have also recently issued reports on MNKD. BidaskClub upgraded shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Maxim Group cut shares of MannKind from a “hold” rating to a “sell” rating and set a $1.00 price target on the stock. in a research report on Wednesday, February 28th. Zacks Investment Research upgraded shares of MannKind from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Thursday, March 29th. Finally, ValuEngine upgraded shares of MannKind from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.76
|
|
|
|
Post by wyattdog on Jun 14, 2018 9:58:05 GMT -5
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of MannKind by 82.8% during the fourth quarter. BlackRock Inc. now owns 3,534,811 shares of the biopharmaceutical company’s stock valued at $8,201,000 after buying an additional 1,600,802 shares during the period. Scopia Capital Management LP bought a new stake in MannKind during the first quarter worth about $2,575,000. Millennium Management LLC boosted its stake in MannKind by 544.7% during the first quarter. Millennium Management LLC now owns 1,039,696 shares of the biopharmaceutical company’s stock worth $2,371,000 after acquiring an additional 878,432 shares in the last quarter. Geode Capital Management LLC boosted its stake in MannKind by 14.7% during the fourth quarter. Geode Capital Management LLC now owns 551,568 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 70,542 shares in the last quarter. Finally, Tibra Equities Europe Ltd bought a new stake in MannKind during the first quarter worth about $608,000. Institutional investors own 19.41% of the company’s stock.
|
|
